Physician profile
Frederic Regenstein
NPI 1609977768
$200,933.85
in general payments reported to CMS, 2019-2025
22 companies · $30K in 2025
The $30K reported for 2025 was more than what 80% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $16K · 2021: $11K · 2022: $23K · 2023: $42K · 2024: $38K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Travel and Lodging: $6,358 · Food and Beverage: $4,485 · Consulting Fee: $1,058 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,188.50 |
| Travel and Lodging | $6,357.99 |
| Food and Beverage | $4,484.86 |
| Consulting Fee | $1,057.50 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $137,931.71 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Mallinckrodt Hospital Products INC. | $33,715.98 | 2020-2024 | Terlivaz |
| Madrigal Pharmaceuticals | $16,490.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Exelixis INC. | $5,436.72 | 2022 | |
| Intercept Pharmaceuticals, INC. | $5,135.12 | 2019-2025 | Ocaliva |
| Celgene Corporation | $1,304.61 | 2019 | |
| Eisai INC. | $245.92 | 2019-2023 | |
| Abbvie INC. | $205.86 | 2019-2020 | |
| Dova Pharmaceuticals | $140.26 | 2019 | |
| W. L. Gore & Associates, INC. | $134.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.75 | 2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $35.22 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $33.30 | 2022-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.18 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Regenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.